Alliance Pharma plc (LON:APH) had its price objective dropped by equities researchers at FinnCap from GBX 65 ($0.84) to GBX 58 ($0.75) in a report released on Monday, July 31st. The firm presently has a “buy” rating on the stock. FinnCap’s target price points to a potential upside of 9.43% from the company’s current price.
Separately, Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 60 ($0.78) target price on shares of Alliance Pharma plc in a report on Tuesday, July 18th.
Alliance Pharma plc (LON APH) opened at 53.00 on Monday. Alliance Pharma plc has a 12-month low of GBX 41.33 and a 12-month high of GBX 57.50. The company has a 50-day moving average of GBX 52.54 and a 200 day moving average of GBX 50.15. The company’s market capitalization is GBX 250.54 million.
WARNING: This piece of content was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/alliance-pharma-plc-lonaph-price-target-lowered-to-gbx-58-at-finncap-updated-updated.html.
About Alliance Pharma plc
Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.
What are top analysts saying about Alliance Pharma plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alliance Pharma plc and related companies.